We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-0.98%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$303M
AUM Growth
-$17.4M
Cap. Flow
-$10.2M
Cap. Flow %
-3.35%
Top 10 Hldgs %
82.65%
Holding
26
New
4
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
SBBP
Strongbridge Biopharma plc.
SBBP
+$12.2M
2
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$4.62M
3
TMBR
Timber Pharmaceuticals, Inc.
TMBR
+$4.37M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.78M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.99M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$23.1M
2
RGNX icon
Regenxbio
RGNX
+$9.32M
3
AGRX
Agile Therapeutics
AGRX
+$3.55M
4
PTN
Palatin Technologies
PTN
+$148K
5
KALV
KalVista Pharmaceuticals
KALV
+$7

Sector Composition

Rank Sector Weight
1 Healthcare 91.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$739M
$89.1M 29.37%
3,283,569
-907,828
-22% -$23.1M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.3B
$35.8M 11.78%
1,766,832
– –
CDXS icon
3
Codexis
CDXS
$136M
$24.4M 8.03%
5,294,825
– –
NBRV
4
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$24M 7.9%
16,086
+3,479
+28% +$4.62M
EIGR
5
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$20.8M 6.86%
59,570
– –
AIMT
6
DELISTED
Aimmune Therapeutics
AIMT
$15.6M 5.14%
763,009
– –
AAAP
7
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$12.2M 4.02%
455,798
– –
TRVN
8
DELISTED
Trevena, Inc.
TRVN
$10.2M 3.35%
2,765
– –
FOMX
9
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$9.49M 3.13%
855,000
– –
RGNX icon
10
Regenxbio
RGNX
$606M
$9.33M 3.07%
502,863
-487,586
-49% -$9.32M
AGRX
11
DELISTED
Agile Therapeutics
AGRX
$8.63M 2.84%
757
-253
-25% -$3.55M
CLCD
12
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$8.19M 2.7%
225,000
– –
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
$7.2M 2.37%
+3,000,000
New +$12.2M
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
$6.04M 1.99%
99,426
– –
TMBR
15
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$4.79M 1.58%
+854
New +$4.37M
AKTX
16
Akari Therapeutics
AKTX
$14.4M
$3.72M 1.22%
660
– –
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.63M 1.2%
60,957
– –
CRSP icon
18
CRISPR Therapeutics
CRSP
$4.64B
$3.02M 0.99%
+148,878
New +$2.78M
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$2.12M 0.7%
300,325
-1
-0% -$7
VIRX
20
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.81M 0.6%
+14,286
New +$1.99M
RVNC
21
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.6M 0.53%
77,373
– –
DVAX
22
DELISTED
Dynavax Technologies
DVAX
$1.42M 0.47%
359,828
– –
OCRX
23
DELISTED
Ocera Therapeutics, Inc.
OCRX
$322K 0.11%
153,331
– –
ZSAN
24
DELISTED
Zosano Pharma Corporation
ZSAN
$77K 0.03%
141
– –
CAPNW
25
DELISTED
Capnia, Inc. Series A Warrant
CAPNW
$76K 0.03%
943,858
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Vivo Capital held 26 positions worth $303M, down 5.4% from $321M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Vivo Capital withdrew a net $10.2M in Q4 2016, closing 1 position and reducing 4 holdings. Its most notable exit was Palatin Technologies, an estimated $148K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

Against the trend, Vivo Capital opened a new position in Strongbridge Biopharma plc. worth $7.2M.

  • Vivo Capital's largest Q4 2016 buy was Strongbridge Biopharma plc.: 3,000,000 shares worth $7.2M.
  • Vivo Capital added most to Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2016, an estimated $4.62M increase.
  • Vivo Capital's biggest Q4 2016 reduction was Aclaris Therapeutics, cutting an estimated $23.1M.
  • Vivo Capital fully exited Palatin Technologies in Q4 2016, selling an estimated $148K.
  • Vivo Capital's ten largest holdings make up 83% of its $303M portfolio in Q4 2016.
  • Vivo Capital opened 4 new positions and closed 1 in Q4 2016.
  • Vivo Capital's portfolio value fell 5.4% quarter-over-quarter to $303M.

Based on Vivo Capital's 13F filing for Q4 2016, filed 14 Feb 2017.